NurExone Biologic

Company Overview

Snapshot

Founded in January 2020, NurExone Biologic operates with 11–50 employees and has raised a total of $9.53M across 8 funding rounds. The company went public on the TSXV in July 2022.

Business overview

NurExone Biologic is a Health Tech & Life Sciences company focused on revolutionizing recovery from central nervous system injuries. The company is developing a biological extracellular vesicles-based drug platform designed to regenerate and rewire neurons. Its novel approach to spinal cord injury (SCI) treatment utilizes intranasal exosome administration, offering an alternative to existing therapies. NurExone operates within the Drugs Discovery & Development sector, targeting the Pharmaceuticals market with its exosome-based therapies.

Strategic signal

In September 2025, NurExone Biologic received a U.S. patent allowance for its exosome manufacturing process, which strengthens its supply chain readiness. This development signals to investors a significant step towards commercialization and scaling production of its EV-based drug platform, enhancing the company's position in the regenerative medicine market.

Company Intelligence Q&A

What was a key regulatory milestone achieved by NurExone Biologic in 2023?

In October 2023, NurExone Biologic received FDA Orphan-Drug Designation for its ExoPTEN therapy, aimed at accelerating the development of acute spinal cord injury treatment.

What strategic move did NurExone Biologic make regarding its manufacturing capabilities in 2025?

In September 2025, NurExone announced plans to establish its first U.S. commercial manufacturing facility in Indiana, strengthening its production capabilities and market presence.

What was the outcome of NurExone Biologic's preclinical study on ExoPTEN in 2024?

In September 2024, NurExone demonstrated an extended therapeutic window for ExoPTEN post spinal-cord injury in a preclinical study, indicating potential for broader clinical application.

What was a significant corporate development for NurExone Biologic in November 2024?

In November 2024, NurExone Biologic secured EMA Orphan Status for ExoPTEN in Spinal Cord Injury, accelerating its pathway to European markets.

What was NurExone Biologic's financial activity in November 2025?

In November 2025, NurExone Biologic secured over C$3.18 Million through accelerated warrant exercises, providing additional capital for its operations.